Cytyc Earnings in Line

It matches the 27-cent consensus estimate.
Author:
Publish date:

Cytyc

(CYTC)

said fourth-quarter earnings rose 31%, aided by strong sales, especially in surgical products.

The Marlborough, Mass.-based women's healthcare provider earned $33.4 million, or 27 cents a share, in the quarter, compared with $25.4 million, or 21 cents a share, a year ago. Analysts polled by Thomson First Call were expecting earnings of $33.73 million, or 27 cents a share.

Fourth-quarter revenue rose 25% to $138.6 million. Analysts were expecting revenue of $138.29 million.

Revenue from diagnostic products, which contributed 68.3% of the total revenue of the quarter, grew 10%. Surgical products revenue jumped 80% over the corresponding quarter of 2004, contributing more than 31% of total revenue for the quarter. Surgical products revenue consists mainly of sales of the NovaSure System and the MammoSite Radiation Therapy System, both of which were acquired by Cytyc in March 2005 and March 2004 respectively.

Operating margin remained constant at 48% for the current and corresponding quarters.

This story was created through a joint venture between TheStreet.com and IRIS.